The End of the National Launch: Why Regional Pharma Market Access Now Determines Commercial Success

Author(s): Manoj Sood

For years, the pharmaceutical industry has treated national approval as the defining milestone of launch success. Secure pricing and reimbursement; publish the value dossier; brief the field teams; and expect uptake to follow.

But across Europe – and increasingly in other mature markets – the reality is far more complex. Even with strong national HTA outcomes, adoption varies dramatically across regions, networks, and hospitals at the sub-national level. Patients in one area gain rapid access, while those a few miles away wait months, or never receive the therapy at all.

This is not a tactical execution issue. It’s a structural shift in how health systems operate. The national launch model no longer reflects where decisions are made or how medicines reach patients. Today, commercial performance depends on mastering regional pharma market access: the subnational layer where funding, prioritization, and implementation decisions actually occur.

Companies that continue to rely on national-only strategies will see inconsistent uptake and missed opportunities. Those that build strong regional capabilities will outperform. And it’s not because they have better products. It’s because they understand how decisions are made in the real world.